Literature DB >> 11917236

Comparative analysis of HIV-1 viral load assays on subtype quantification: Bayer Versant HIV-1 RNA 3.0 versus Roche Amplicor HIV-1 Monitor version 1.5.

Tarek Elbeik1, W Gregory Alvord, Rapee Trichavaroj, Mark de Souza, Robin Dewar, Arthur Brown, David Chernoff, Nelson L Michael, Patricia Nassos, Keith Hadley, Valerie L Ng.   

Abstract

Quantification of HIV-1 subtypes is essential for appropriate clinical management. Whereas viral load assays were initially developed to accurately quantify subtype B, the recent worldwide spread of non-B subtypes and the introduction of treatment programs in regions with non-B subtypes have prompted adaptations of these assays. The Bayer Versant HIV-1 RNA 3.0 Assay (branched DNA [bDNA] 3.0) and the Roche Amplicor HIV-1 Monitor version 1.5 (Amplicor 1.5) assays are reported to quantify all subtypes in group M; however, evaluation of performance characteristics remains limited. In this study, we evaluated the accuracy and reliability of bDNA 3.0 and Amplicor 1.5 on multiple serially diluted viral isolates from HIV-1 group M, subtypes A through F. Testing was conducted on both assay systems in two independent laboratories. Comparative pansubtype quantification from regression analysis showed that quantification by bDNA 3.0 was approximately 0.3 log-fold lower than that by Amplicor 1.5. Comparative pansubtype accuracy analysis showed data points more closely distributed about their respective regression lines and thus showing greater reliability by bDNA 3.0 than by Amplicor 1.5.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11917236     DOI: 10.1097/00126334-200204010-00002

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  21 in total

1.  Comparison of LCx with other current viral load assays for detecting and quantifying human immunodeficiency virus type 1 RNA in patients infected with the circulating recombinant form A/G (CRF02).

Authors:  Alessandra Amendola; Licia Bordi; Claudio Angeletti; Enrico Girardi; Giuseppe Ippolito; Maria R Capobianchi
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

2.  Use of sequence data generated in the Bayer Tru Gene genotyping assay to recognize and characterize non-subtype-b human immunodeficiency virus type 1 strains.

Authors:  Diane L Hirigoyen; Charles P Cartwright
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

3.  Comparison of the LCx human immunodeficiency virus (HIV) RNA quantitative, RealTime HIV, and COBAS AmpliPrep-COBAS TaqMan assays for quantitation of HIV type 1 RNA in plasma.

Authors:  Vincent Foulongne; Brigitte Montes; Marie-Noelle Didelot-Rousseau; Michel Segondy
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

4.  Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT.

Authors:  Priscilla Swanson; Carmen de Mendoza; Yagnya Joshi; Alan Golden; Richard L Hodinka; Vincent Soriano; Sushil G Devare; John Hackett
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

Review 5.  Targeting viral reservoirs: ability of antiretroviral therapy to stop viral replication.

Authors:  Frank Maldarelli
Journal:  Curr Opin HIV AIDS       Date:  2011-01       Impact factor: 4.283

Review 6.  Diagnosis of Human Immunodeficiency Virus Infection.

Authors:  Bharat S Parekh; Chin-Yih Ou; Peter N Fonjungo; Mireille B Kalou; Erin Rottinghaus; Adrian Puren; Heather Alexander; Mackenzie Hurlston Cox; John N Nkengasong
Journal:  Clin Microbiol Rev       Date:  2018-11-28       Impact factor: 26.132

7.  Evaluation of the clinical sensitivities of three viral load assays with plasma samples from a pediatric population predominantly infected with human immunodeficiency virus type 1 subtype G and BG recombinant forms.

Authors:  Rute Antunes; Sofia Figueiredo; Inês Bártolo; Manuel Pinheiro; Lino Rosado; Isabel Soares; Helena Lourenço; Nuno Taveira
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

8.  Simultaneous runs of the Bayer VERSANT HIV-1 version 3.0 and HCV bDNA version 3.0 quantitative assays on the system 340 platform provide reliable quantitation and improved work flow.

Authors:  Tarek Elbeik; Norman Markowitz; Patricia Nassos; Uday Kumar; Scott Beringer; Barbara Haller; Valerie Ng
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

9.  HIV populations are large and accumulate high genetic diversity in a nonlinear fashion.

Authors:  Frank Maldarelli; Mary Kearney; Sarah Palmer; Robert Stephens; JoAnn Mican; Michael A Polis; Richard T Davey; Joseph Kovacs; Wei Shao; Diane Rock-Kress; Julia A Metcalf; Catherine Rehm; Sarah E Greer; Daniel L Lucey; Kristen Danley; Harvey Alter; John W Mellors; John M Coffin
Journal:  J Virol       Date:  2013-05-15       Impact factor: 5.103

10.  Viral load levels measured at set-point have risen over the last decade of the HIV epidemic in the Netherlands.

Authors:  Luuk Gras; Suzanne Jurriaans; Margreet Bakker; Ard van Sighem; Daniela Bezemer; Christophe Fraser; Joep Lange; Jan M Prins; Ben Berkhout; Frank de Wolf
Journal:  PLoS One       Date:  2009-10-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.